Loading
A phase 2 trial of Carboplatin and Cetuximab in advanced solid tumours, run by US Oncology Research, active and no longer recruiting.
PhII ICb With/Without Erbitux in MBC Pts is a phase 2 interventional study registered as NCT00248287 by US Oncology Research, with 154 participants enrolled, started 2005-07-28 and due to reach its primary completion in 2025-12. Interventions recorded: Irinotecan + Carboplatin and irinotecan + Carboplatin + erbitux. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
154 enrolled.
95% CI 24.9 to 49.1; Figures from the ClinicalTrials.gov results section (first posted 2016-11-03), not from a publication · 95% CI 25.5 to 48.9
Source95% CI 10.6 to 17.1; Figures from the ClinicalTrials.gov results section (first posted 2016-11-03), not from a publication · 95% CI 10.4 to 16.9
Source95% CI 3.2 to 5.8; Figures from the ClinicalTrials.gov results section (first posted 2016-11-03), not from a publication · 95% CI 3.5 to 5.5
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective Response Rates (ORR)primary | Irinotecan+Carboplatin | 66 | 36.4% | - | - | link |
| Irinotecan+Carboplatin+Cetuximab | 71 | 36.6% | ||||
| Median Overall Survival (OS) | Irinotecan+Carboplatin | 75 | 12.5 months | - | - | link |
| Irinotecan+Carboplatin+Cetuximab | 79 | 14.6 months | ||||
| Median Time of Progression-free Survival (PFS) | Irinotecan+Carboplatin | 75 | 4.4 months | - | - | link |
| Irinotecan+Carboplatin+Cetuximab | 79 | 4.6 months |
Shares McKesson / The US Oncology Network, Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Platinum agents, Carboplatin, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Bristol Myers Squibb, Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pfizer (incl. Seagen), Monoclonal antibodies, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Cetuximab, Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Platinum agents, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Cetuximab, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Platinum agents, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.